Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Pharma Lobby Calls For Re-examination Of 81 MNC Drug Patents

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As Indian companies battle multinational drug giants for patent rights, the Indian Pharmaceutical Alliance - an association that represents top Indian drug companies - wrote to the Union Ministry of Commerce and Industry Feb. 14 that a large number of pharmaceutical patents granted over the last four years are granted to new forms of known substances and combinations of old drugs

You may also be interested in...



Its Advantage Roche As Indian Patent Office Rejects Valcyte Opposition By Indian Groups

MUMBAI - Swiss drug maker Roche has gained a significant lead against two non-government organizations in its fight over patents of anti-infection drug Valcyte (valgancyclovir) after India's Controller of Patents rejected their pleas for pre-grant opposition

Insider Analysis: The Glivec Patent Saga – Effectuating “Efficacious” Patent Norms In India

By: Shamnad Basheer

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel